| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5744496 | ABBVIE | Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors |
Apr, 2015
(9 years ago) | |
Mavik is owned by Abbvie.
Mavik contains Trandolapril.
Mavik has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Mavik are:
- US5744496
Mavik was authorised for market use on 26 April, 1996.
Mavik is available in tablet;oral dosage forms.
Mavik can be used as cardiac insufficiency (congestive heart failure).
The generics of Mavik are possible to be released after 28 April, 2015.
Drugs and Companies using TRANDOLAPRIL ingredient
Market Authorisation Date: 26 April, 1996
Treatment: Cardiac insufficiency (congestive heart failure)
Dosage: TABLET;ORAL
How can I launch a generic of MAVIK before it's drug patent expiration?
More Information on Dosage
MAVIK family patents
